翰森製藥(03692.HK)聯手魚鷹資管成立博勝藥業
翰森製藥(03692.HK)宣佈,與魚鷹資產管理(Cormorant Asset Management)共同創立並孵化的博勝藥業(Blossom Biosciences)正式成立,博勝藥業將致力於爲更多中國患者帶來潛在的突破性治療藥物,目前已完成由翰森製藥和魚鷹資管共同領投的7,200萬美元A輪融資。
博勝藥業與翰森製藥達成協議,由翰森製藥爲其提供臨牀前、臨牀和商業化支持,以加快產品管線在中國的研發和上市。魚鷹資管將通過其豐富的全球生物醫藥資源和投資組合公司,支持博勝藥業引入創新產品。魚鷹資管董事總經理、C4 Therapeutics, Inc.(CCCC.US)前CEO Andrew Phillips已被任命爲博勝藥業的代理CEO。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.